Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The role of iron chelation therapy in myelodysplastic syndrome (MDS) remains controversial. Averting cardiac dysfunction in low-grade MDS patients who have sufficient longevity to experience deleterious cardiac effects of iron overload has been the major argument in favor of iron chelation. Although there is significant evidence showing the adverse impact of transfusion dependency on survival in MDS, direct evidence linking tissue iron overload to poor survival or in particular to cardiac dysfunction is lacking. Given the heterogeneity of MDS, it is likely that the pathophysiology of iron overload is equally heterogeneous and complex in these patients. In this article, I argue that prevention of cardiac dysfunction in patients with lower grades of MDS may not be the major benefit of iron chelation therapy, and present evidence suggesting a potential benefit of iron chelation on 3 other outcomes, namely (1) lowering infection risk, (2) improving the outcome of allogeneic hematopoietic stem cell transplantation, and (3) delaying leukemic transformation. These outcomes have particular relevance for patients with higher grades of MDS and should be evaluated in future prospective clinical trials that include patients with all grades of MDS to fully evaluate the benefit of iron chelation therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin
Tanno, T., Bhanu, N. V., Oneal, P. A., Goh, S.-H., Staker, P., Lee, Y. T., Moroney, J. W., Reed, C. H., Luban, N. L., Wang, R.-H., et al. (2007) · Nature Medicine · doi:10.1038/nm1629 · Cited by 854
Labile plasma iron in iron overload: redox activity and susceptibility to chelation
Esposito, B. P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C., & Cabantchik, Z. I. (2003) · Blood · doi:10.1182/blood-2003-03-0807 · Cited by 475
Armand, P., Kim, H. T., Cutler, C. S., Ho, V. T., Koreth, J., Alyea, E. P., Soiffer, R. J., & Antin, J. H. (2007) · Blood · doi:10.1182/blood-2006-10-054924 · Cited by 426
Natural resistance, iron and infection: a challenge for clinical medicine
Bullen, J. J., Rogers, H. J., Spalding, P. B., & Ward, C. G. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46386-0 · Cited by 163
Kontoyiannis, D. P., Chamilos, G., Lewis, R. E., Giralt, S., Cortes, J., Raad, I. I., Manning, J. T., & Han, X. (2007) · Cancer · doi:10.1002/cncr.22909 · Cited by 152
Karp, J. E., & Merz, W. G. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.2.216 · Cited by 35
Cited by
Callens, C., Coulon, S., Naudin, J., Radford-Weiss, I., Boissel, N., Raffoux, E., Wang, P. H. M., Agarwal, S., Tamouza, H., Paubelle, E., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091488 · Cited by 197
“…and enhancing time to progression, could act at multi ple levels: by preventing red cell transfusionderived secondary iron overload, by avoiding defective bone marrow reconsti tution after allogeneic HSCT, and also by improving patients’ immune status (Pullarkat et al., 2008; Pullarkat, 2009).”
Background‘Ride on the ferrous wheel’ – The cycle of iron in macrophages in health and disease
Nairz, M., Schroll, A., Demetz, E., Tancevski, I., Theurl, I., & Weiss, G. (2015) · Immunobiology · doi:10.1016/j.imbio.2014.09.010 · Cited by 89
Risk and timing of cardiovascular death among patients with myelodysplastic syndromes
Brunner, A. M., Blonquist, T. M., Hobbs, G. S., Amrein, P. C., Neuberg, D. S., Steensma, D. P., Abel, G. A., & Fathi, A. T. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010165 · Cited by 63
Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent Developments
Leitch, H. A. (2011) · Drugs · doi:10.2165/11585280-000000000-00000 · Cited by 17
Metadata
- Authors
- Pullarkat, V.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-12-17
- Volume
- 114
- Issue
- 26
- Pages
- 5251-5255
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2015814229
- Cited by
- 108
- References
- 7
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? https://app.cochat.ai/papers/10.1182/blood-2009-07-234062
- The paper
- Pullarkat, V. (2009). Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood. https://doi.org/10.1182/blood-2009-07-234062
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.